Organoids & Organ-on-Chip Microphysiological Systems: Experimental Design, Validation & Preclinical Drug Testing

This workshop aims to provide participants with a practical understanding of how organoids, organ-on-chip platforms, and microphysiological systems are designed, validated, and applied in preclinical drug testing. Participants will learn how to select appropriate models, define experimental conditions, evaluate model quality, interpret dose-response data, and support preclinical decision-making.

• Understand the principles of organoids, spheroids, organ-on-chip platforms, and microphysiological systems.
• Select appropriate cell sources, organ models, extracellular matrices, and experimental platforms.
• Design controls, replicates, exposure conditions, endpoints, and experimental workflows.
• Assess biological, functional, and engineering validation parameters.
• Evaluate morphology, biomarkers, barrier function, tissue-specific responses, reproducibility, and assay variability.
• Design drug exposure and concentration-response experiments.
• Interpret IC50, EC50, efficacy, toxicity, and organ-specific safety data.
• Integrate multiple biological and functional readouts for preclinical assessment.
• Translate MPS-derived data into evidence-based preclinical decisions.

• Undergraduate and postgraduate students in Biotechnology, Biomedical Sciences, Life Sciences, Pharmacy, Bioengineering, and related disciplines.
• PhD scholars and research fellows working in organoids, tissue engineering, toxicology, pharmacology, regenerative medicine, or drug discovery.
• Faculty members and academic researchers interested in advanced in vitro models and microphysiological systems.
• Pharmaceutical, biotechnology, CRO, and preclinical research professionals involved in drug screening, efficacy testing, safety assessment, and toxicology.
• Researchers interested in alternatives to conventional animal models and human-relevant preclinical testing platforms.

• Design a fit-for-purpose organoid or organ-on-chip experiment.
• Select suitable controls, exposure conditions, endpoints, and validation criteria.
• Evaluate organoid and organ-on-chip models using predefined quality-control metrics.
• Interpret viability, biomarker, functional, and variability datasets.
• Generate and interpret drug concentration-response curves.
• Assess drug efficacy and toxicity using organ-specific readouts.
• Integrate multiple experimental endpoints for comprehensive drug assessment.
• Analyze liver organoid-on-chip drug-testing data and identify potential toxicity signals.
• Make scientifically justified preclinical go/no-go decisions based on MPS data.